The current investigation took this clinical question seriously and raised the bar for predicting molecular alterations in gliomas by restricting the analyzed cohort to WHO grade II/III gliomas and was able to prove not only that IDH mutation can be classified at a reasonable accuracy but also that the classification accuracy of the pTERT mutation can be improved by a CNN, which warrants future investigations for training the CNN itself with a WHO grade II/III glioma-restricted cohort. This evidence concerns the gene IDH2 and central nervous system cancer.